

Roberto Marchioli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1050828/publications.pdf>

Version: 2024-02-01

117
papers

14,393
citations

61977

43
h-index

23530

111
g-index

121
all docs

121
docs citations

121
times ranked

14232
citing authors

#	ARTICLE	IF	CITATIONS
1	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet, The</i> , 2010, 375, 735-742.	13.7	2,064
2	Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction. <i>Circulation</i> , 2002, 105, 1897-1903.	1.6	1,213
3	Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 372, 1231-1239.	13.7	954
4	Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. <i>New England Journal of Medicine</i> , 2004, 350, 114-124.	27.0	911
5	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. <i>New England Journal of Medicine</i> , 2013, 368, 22-33.	27.0	664
6	Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera. <i>Journal of Clinical Oncology</i> , 2005, 23, 2224-2232.	1.6	631
7	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015, 385, 351-361.	13.7	562
8	Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , 2018, 3, 225.	6.1	526
9	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	13.7	512
10	n-3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors. <i>New England Journal of Medicine</i> , 2013, 368, 1800-1808.	27.0	464
11	Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. <i>Blood</i> , 2005, 105, 2664-2670.	1.4	389
12	Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. <i>Blood</i> , 2007, 109, 2446-2452.	1.4	356
13	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. <i>Haematologica</i> , 2008, 93, 372-380.	3.5	316
14	Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. <i>Blood</i> , 2007, 109, 2310-2313.	1.4	295
15	Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1368-1377.	2.4	287
16	Omega-3 Fatty Acids for Cardioprotection. <i>Mayo Clinic Proceedings</i> , 2008, 83, 324-332.	3.0	218
17	Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 635-641.	7.1	214
18	Fish Oil and Postoperative Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2001.	7.4	201

#	ARTICLE	IF	CITATIONS
19	A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. <i>American Heart Journal</i> , 2007, 153, 1037-1047.	2.7	200
20	The haematocrit and platelet target in polycythemia vera. <i>British Journal of Haematology</i> , 2007, 136, 249-259.	2.5	162
21	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. <i>Haematologica</i> , 2011, 96, 315-318.	3.5	160
22	Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. <i>Lancet</i> , The, 2007, 370, 667-675.	13.7	153
23	Aspirin Therapy in Primary Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 319-327.	2.8	150
24	Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 277-283.	2.8	147
25	The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI heart failure (GISSI-HF) trial. <i>European Journal of Heart Failure</i> , 2010, 12, 338-347.	7.1	129
26	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.	2.2	126
27	Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. <i>American Heart Journal</i> , 2010, 159, 245-257.	2.7	106
28	Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. <i>European Journal of Heart Failure</i> , 2005, 7, 904-909.	7.1	101
29	Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 65-72.	3.9	101
30	Predictors of Mortality in 6975 Patients With Chronic Heart Failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2013, 6, 31-39.	3.9	101
31	Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. <i>European Heart Journal</i> , 2009, 30, 2327-2336.	2.2	98
32	Cholesterol Reduction and Stroke Occurrence: An Overview of Randomized Clinical Trials. <i>Cerebrovascular Diseases</i> , 2000, 10, 85-92.	1.7	97
33	Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 347-350.	1.5	96
34	Cholesterol-Lowering Interventions and Stroke. <i>Journal of the American College of Cardiology</i> , 2010, 55, 198-211.	2.8	88
35	Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2010, 12, 1345-1353.	7.1	75
36	Diet and gallstones in Italy: The cross-sectional MICOL results. <i>Hepatology</i> , 1998, 27, 1492-1498.	7.3	70

#	ARTICLE	IF	CITATIONS
37	Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 183-190.	1.9	68
38	European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): A Randomized Trial. <i>Seminars in Thrombosis and Hemostasis</i> , 1997, 23, 473-478.	2.7	64
39	Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2012, 14, 1410-1419.	7.1	64
40	Coffee Consumption and Risk of Cardiovascular Events After Acute Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2944-2951.	1.6	55
41	Fish Oil and Post-Operative Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2194-2196.	2.8	52
42	Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases. <i>Current Cardiology Reports</i> , 2000, 2, 293-299.	2.9	51
43	Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. <i>Cardiology</i> , 2017, 136, 128-137.	1.4	46
44	Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	43
45	Wine consumption and risk of cardiovascular events after myocardial infarction: Results from the GISSI-Prevenzione trial. <i>International Journal of Cardiology</i> , 2013, 163, 282-287.	1.7	42
46	Meta-Analysis of Effect of Statin Treatment on Risk of Sudden Death. <i>American Journal of Cardiology</i> , 2007, 100, 1644-1650.	1.6	41
47	Uric acid: A cardiovascular risk factor in patients with recent myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 167, 262-269.	1.7	41
48	A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis.. <i>Blood</i> , 2007, 110, 3540-3540.	1.4	39
49	Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 735-748.	1.5	37
50	Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. <i>International Journal of Cardiology</i> , 2014, 172, 403-410.	1.7	36
51	Fish Oil and Perioperative Bleeding. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004584.	2.2	36
52	Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 242-251.e10.	0.8	34
53	n-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1289-1295.	7.1	33
54	Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. <i>European Heart Journal</i> , 2007, 28, 1977-1983.	2.2	31

#	ARTICLE	IF	CITATIONS
55	The ω -3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trial—rationale and design. American Heart Journal, 2011, 162, 56-63.e3.	2.7	31
56	Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico—Heart Failure trial. Nutrition Research, 2016, 36, 989-994.	2.9	30
57	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza) Tj ETQq1 1 0.784314 rgBT /Overlaid 3.4 30 205-215.	3.4	30
58	Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leukemia and Lymphoma, 2015, 56, 2543-2551.	1.3	29
59	GISSI-Prevenzione trial. Lancet, The, 1999, 354, 1556-1557.	13.7	26
60	BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. British Journal of Haematology, 1997, 99, 379-385.	2.5	24
61	Plasma Phospholipid Omega-3 Fatty Acids and Incidence of Postoperative Atrial Fibrillation in the OPERA Trial. Journal of the American Heart Association, 2013, 2, e000397.	3.7	24
62	n-3PUFA and Holter-derived autonomic variables in patients with heart failure: Data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy. Heart Rhythm, 2013, 10, 226-232.	0.7	23
63	Circulating cardiac biomarkers and postoperative atrial fibrillation in the OPERA trial. European Journal of Clinical Investigation, 2015, 45, 170-178.	3.4	23
64	Family history and socioeconomic factors as predictors of myocardial infarction, unstable angina and stroke in an Italian population. European Journal of Epidemiology, 1996, 12, 177-185.	5.7	22
65	Omega-3 fatty acids and heart failure. Current Atherosclerosis Reports, 2009, 11, 440-447.	4.8	22
66	n-3 PUFAs in cardiovascular disease. International Journal of Cardiology, 2013, 170, S33-S38.	1.7	21
67	Polycythemia vera: gender-related phenotypic differences. Internal and Emergency Medicine, 2012, 7, 509-515.	2.0	19
68	A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).. Blood, 2009, 114, 754-754.	1.4	19
69	Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. American Journal of Hematology, 2010, 85, 616-619.	4.1	18
70	Prognostic impact of metabolic syndrome in patients with chronic heart failure: Data from GISSI-HF trial. International Journal of Cardiology, 2015, 178, 85-90.	1.7	18
71	Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT. Atherosclerosis, 2016, 248, 216-218.	0.8	18
72	Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. Vascular Health and Risk Management, 2006, 2, 507-514.	2.3	18

#	ARTICLE	IF	CITATIONS
73	Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 44, 16-23.	2.6	16
74	Cardiovascular risk changes after lipid lowering medications: are they predictable?. <i>Atherosclerosis</i> , 2000, 152, 1-8.	0.8	14
75	Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins – Confirmation from PCSK9 Inhibitor Studies. <i>American Journal of Medicine</i> , 2020, 133, 95-99.e6.	1.5	14
76	Analysis of the Benefits of a Mediterranean Diet in the GISSI-Prevenzione Study: A Case Study in Imputation of Missing Values from Repeated Measurements. <i>European Journal of Epidemiology</i> , 2006, 21, 15-24.	5.7	12
77	A low plasma 1,25(OH) ₂ vitamin D/PTH (1/84) ratio predicts worsening of renal function in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 220-225.	1.7	12
78	Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. <i>Haematologica</i> , 2013, 98, 1421-1423.	3.5	11
79	A Positive Relation between High Hemoglobin Values and the Risk of Ischemic Stroke. <i>European Neurology</i> , 1996, 36, 85-88.	1.4	10
80	Clinical Trials in Myeloproliferative Disorders: Looking Forward. <i>Seminars in Hematology</i> , 2005, 42, 259-265.	3.4	9
81	n-3 PUFAs and heart failure. <i>International Journal of Cardiology</i> , 2013, 170, S28-S32.	1.7	9
82	Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1997, 96, 620-626.	2.5	8
83	Hypertension Optimal Treatment (HOT) trial. <i>Lancet</i> , The, 1998, 352, 571-572.	13.7	8
84	Cancer in chronic heart failure patients in the GISSI-HF trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13273.	3.4	8
85	Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial. <i>Blood</i> , 2012, 120, 550-550.	1.4	8
86	Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. <i>Haematologica</i> , 2005, 90, 851-3.	3.5	8
87	Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease. <i>Journal of Multidisciplinary Healthcare</i> , 2010, 3, 79.	2.7	7
88	Modes of death and prognostic outliers in chronic heart failure. <i>American Heart Journal</i> , 2019, 208, 100-109.	2.7	7
89	A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results. <i>Blood</i> , 2010, 116, 314-314.	1.4	7
90	Prospective Evaluation of Clinico-Pathological Predictors of Postoperative Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008382.	4.8	6

#	ARTICLE	IF	CITATIONS
91	Fish Oil Supplementation Does Not Affect Cognitive Outcomes in Cardiac Surgery Patients in the Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) Trial. <i>Journal of Nutrition</i> , 2018, 148, 472-479.	2.9	5
92	IGENDA protocol: gender differences in awareness, knowledge and perception of cardiovascular risk: An Italian multicenter study. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 278-283.	1.5	5
93	Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects. <i>Thrombosis and Haemostasis</i> , 2002, 87, 58-67.	3.4	5
94	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. <i>Blood</i> , 2013, 122, 1583-1583.	1.4	4
95	Prognosis of Venous Occlusive Disease after Stem Cell Transplantation in the DF-VOD Trial. On behalf of the DF-VOD Investigators... <i>Blood</i> , 2004, 104, 1137-1137.	1.4	4
96	Chronic infections and coronary heart disease. <i>Lancet</i> , The, 1997, 350, 1028-1029.	13.7	3
97	Global cardiovascular risk evaluation. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 581-586.	1.5	3
98	A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial). <i>Blood</i> , 2012, 120, 4-4.	1.4	3
99	Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL). <i>Blood</i> , 2012, 120, 746-746.	1.4	3
100	Clinical Significance of JAK2V617F Homozygosity in the Chronic Myeloproliferative Disorders. A Study on 1306 Patients.. <i>Blood</i> , 2006, 108, 664-664.	1.4	3
101	Why Do We Still Need Large Scale Clinical Trial: The Case of n ³ PUFA. <i>Frontiers in Physiology</i> , 2012, 3, 202.	2.8	2
102	Fish Oil vs Olive Oil for Postoperative Atrial Fibrillation—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 871.	7.4	2
103	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. <i>Blood</i> , 2011, 118, 1750-1750.	1.4	2
104	Correlation of Novel Molecular Markers in Patients with Myeloproliferative Neoplasms.. <i>Blood</i> , 2009, 114, 4968-4968.	1.4	2
105	The yield of meta-analysis. <i>Lancet</i> , The, 1998, 351, 915-916.	13.7	1
106	Current Treatment Approaches of Polycythemia Vera. <i>Clinical Leukemia</i> , 2006, 1, 41-45.	0.2	1
107	Corrigendum to “Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial” [Eur J Heart Fail 2010;12:1345-1353]. <i>European Journal of Heart Failure</i> , 2011, 13, 1042-1042.	7.1	1
108	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. <i>Data in Brief</i> , 2016, 7, 1541-1550.	1.0	1

#	ARTICLE	IF	CITATIONS
109	How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort. <i>Blood</i> , 2012, 120, 1748-1748.	1.4	1
110	Leukocytosis as an Independent Risk Factor for Thrombosis in Polycythemia Vera.. <i>Blood</i> , 2006, 108, 115-115.	1.4	1
111	A GITIL Prospective Randomized Multicenter Phase III Study of High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Transplantation (ASCT) of Peripheral Blood Stem Cells Versus CHOP and Rituximab Delivered Every 14 Days (R-CHOP-14) in High-Risk Patients with Diffuse Large B-Cell Lymphomas (DLBCL): Interim Analysis on Feasibility and Toxicity (Protocol R-HDS 0305).. <i>Blood</i> , 2007, 110, 1898-1898.	1.4	1
112	Pediatric-Type Therapy Including Lineage-Targeted Methotrexate to Improve Early Minimal Residual Disease Response and Survival In Adult Acute Lymphoblastic Leukemia (ALL): Interim Analysis of Northern Italy Leukemia Group Study 10/07. <i>Blood</i> , 2010, 116, 2131-2131.	1.4	1
113	Are All Fish Equally Close to the Heart?â€“Reply. <i>Mayo Clinic Proceedings</i> , 2008, 83, 724-725.	3.0	0
114	High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.. <i>Blood</i> , 2009, 114, 1220-1220.	1.4	0
115	In Vivo T Cell Depletion with Antithymocyte Globulin or Alemtuzumab for Unrelated Donor Stem Cell Transplantation with Reduced Intensity Conditioning: Results of a Multicenter Randomized Phase II Clinical Trial (The Global Study) From the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2012, 120, 221-221.	1.4	0
116	Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte®) In Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 3901-3901.	1.4	0
117	Abstract 12364: Circulating Cardiac and Inflammatory Biomarkers to Predict Post-Operative Atrial Fibrillation in the OPERA Trial. <i>Circulation</i> , 2014, 130, .	1.6	0